{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:24:34Z","timestamp":1769941474746,"version":"3.49.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:bold>Objectives:<\/jats:bold> Rheumatoid arthritis (RA) is a chronic, inflammatory joint disease with complex pathogenesis involving a variety of immunological events. Recently, it has been suggested that kynurenic acid (KYNA) might be a potential regulator of inflammatory processes in arthritis. KYNA has a definitive anti-inflammatory and immunosuppressive function. The aim of the present study is to investigate the complex effects of a newly synthesized KYNA analog\u2014SZR72 on the <jats:italic>in vitro<\/jats:italic> production of tumor necrosis factor-\u03b1 (TNF-\u03b1), tumor necrosis factor-stimulated gene-6 (TSG-6), calprotectin (SA1008\/9), SA100 12 (EN-RAGE), and HNP1\u20133 (defensin-\u03b1) in the peripheral blood of patients with RA and the various effects of the disease.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients with RA (<jats:italic>n<\/jats:italic> = 93) were selected based on the DAS28 score, medication, and their rheumatoid factor (RF) status, respectively. Peripheral blood samples from 93 patients with RA and 50 controls were obtained, and activated by heat-inactivated <jats:italic>S. aureus<\/jats:italic>. Parallel samples were pretreated before the activation with the KYNA analog N-(2-N, N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride. Following the incubation period (18 h), the supernatants were tested for TNF-\u03b1, TSG-6, calprotectin, S100A12, and HNP1\u20133 content by ELISA.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> SZR72 inhibited the production of the following inflammatory mediators: TNF-\u03b1, calprotectin, S100A12, and HNP1\u20133 in whole blood cultures. This effect was observed in each group of patients in various phases of the disease. The basic (control) levels of these mediators were higher in the blood of patients than in healthy donors. In contrast, lower TSG-6 levels were detected in patients with RA compared to healthy controls. In addition, the KYNA analog exerted a stimulatory effect on the TSG-6 production <jats:italic>ex vivo<\/jats:italic> in human whole blood cultures of patients with RA in various phases of the disease.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> These data further support the immunomodulatory role of KYNA in RA resulting in anti-inflammatory effects and draw the attention to the importance of the synthesis of the KYNA analog, which might have a future therapeutic potential.<\/jats:p>","DOI":"10.3389\/fimmu.2021.632513","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T04:57:05Z","timestamp":1617944225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Kynurenic Acid Analog Attenuates the Production of Tumor Necrosis Factor-\u03b1, Calgranulins (S100A 8\/9 and S100A 12), and the Secretion of HNP1\u20133 and Stimulates the Production of Tumor Necrosis Factor-Stimulated Gene-6 in Whole Blood Cultures of Patients With Rheumatoid Arthritis"],"prefix":"10.3389","volume":"12","author":[{"given":"Attila","family":"Balog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borisz","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferenc","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"Lantos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergely","family":"Toldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e9csei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvette","family":"M\u00e1ndi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2016.02.010","article-title":"Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis","volume":"455","author":"Mateen","year":"2016","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"B4","first-page":"S173","article-title":"TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy","volume":"11","author":"Maini","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10354-015-0344-y","article-title":"Anti-TNF in rheumatoid arthritis: an overview","volume":"165","author":"Radner","year":"2015","journal-title":"Wien Med Wien Med Wochenschr"},{"key":"B6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3899\/jrheum.121035","article-title":"Kynurenic acid in synovial fluid and serum of patients with rheumatoid arthritis, spondyloarthropathy, and osteoarthritis","volume":"40","author":"Parada-Turska","year":"2013","journal-title":"J Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"110820","DOI":"10.1016\/j.exger.2019.110820","article-title":"IDO activation, inflammation and musculoskeletal disease","volume":"131","author":"Ogbechi","year":"2020","journal-title":"Exp Gerontol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1523\/JNEUROSCI.10-09-02965.1990","article-title":"Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors","volume":"10","author":"Swartz","year":"1990","journal-title":"J Neurosci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/0361-9230(92)90184-Y","article-title":"Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain","volume":"28","author":"V\u00e9csei","year":"1992","journal-title":"Brain Res Bull"},{"key":"B10","doi-asserted-by":"publisher","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J Neurosci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1111\/j.1460-9568.2007.05540.x","article-title":"Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats","volume":"25","author":"Stone","year":"2007","journal-title":"Eur J Neurosci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0165-6147(00)01451-6","article-title":"Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection","volume":"21","author":"Stone","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2217\/14796708.3.2.169","article-title":"L-kynurenine: metabolism and mechanism of neuroprotection","volume":"3","author":"Robotka","year":"2008","journal-title":"Future Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00702-011-0681-y","article-title":"The kynurenine system and immunoregulation","volume":"119","author":"M\u00e1ndi","year":"2012","journal-title":"J Neural Transm"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3389\/fimmu.2017.01957","article-title":"Kynurenic acid: the janus-faced role of an immunomodulatory tryptophan metabolite and its link to pathological conditions","volume":"8","author":"Wirthgen","year":"2017","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"22021","DOI":"10.1074\/jbc.M603503200","article-title":"Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35","volume":"281","author":"Wang","year":"2006","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3389\/fimmu.2014.00458","article-title":"The aryl hydrocarbon receptor meets immunology: friend or foe? A little of both","volume":"5","author":"Julliard","year":"2014","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.2174\/092986709789909602","article-title":"Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives","volume":"16","author":"F\u00fcl\u00f6p","year":"2009","journal-title":"Curr Med Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00702-009-0346-2","article-title":"A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study","volume":"117","author":"Marosi","year":"2010","journal-title":"J Neural Transm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00210-011-0605-2","article-title":"Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-\u03b1 (TNF-\u03b1) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils","volume":"383","author":"Tiszlavicz","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00702-011-0721-7","article-title":"Modifications on the carboxylic function of kynurenic acid","volume":"119","author":"F\u00fcl\u00f6p","year":"2012","journal-title":"J Neural Transm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"566582","DOI":"10.3389\/fmed.2020.566582","article-title":"Divergent effects of the N-methyl-D-aspartate receptor antagonist kynurenic acid and the synthetic analog SZR-72 on microcirculatory and mitochondrial dysfunction in experimental sepsis","volume":"7","author":"Juh\u00e1sz","year":"2020","journal-title":"Front Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3389\/fimmu.2019.01406","article-title":"The opposite effects of kynurenic acid and different kynurenic acid analogs on tumor necrosis factor-\u03b1 (TNF-\u03b1) production and tumor necrosis factor-stimulated gene-6 (TSG-6) expression","volume":"10","author":"M\u00e1ndi","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1177\/1535370216681551","article-title":"Calprotectin in rheumatic diseases","volume":"242","author":"Ometto","year":"2017","journal-title":"Exp Biol Med Maywood NJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/00325481.2017.1319729","article-title":"Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis","volume":"129","author":"Bae","year":"2017","journal-title":"Postgrad Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1189\/jlb.0306170","article-title":"S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules","volume":"81","author":"Foell","year":"2007","journal-title":"J Leukoc Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00726-008-0097-7","article-title":"Human S100A12: a novel key player in inflammation?","volume":"36","author":"Pietzsch","year":"2009","journal-title":"Amino Acids"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3389\/fimmu.2018.01298","article-title":"S100A8\/A9 in inflammation","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1128\/IAI.55.3.568-571.1987","article-title":"Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes","volume":"55","author":"Ganz","year":"1987","journal-title":"Infect Immun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"H1817","DOI":"10.1152\/ajpheart.00472.2008","article-title":"Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases","volume":"295","author":"Quinn","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1471-4906(02)02246-9","article-title":"Mammalian defensins in immunity: more than just microbicidal","volume":"23","author":"Yang","year":"2002","journal-title":"Trends Immunol"},{"key":"B32","first-page":"1719","article-title":"Intraarticular release and accumulation of defensins and bactericidal\/permeability-increasing protein in patients with rheumatoid arthritis","volume":"30","author":"Bokarewa","year":"2003","journal-title":"J Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3233\/BMR-160743","article-title":"A useful marker in the assessment of remission and activation of disease in patients with rheumatoid arthritis: serum human neutrophil peptides 1-3","volume":"31","author":"Okcu","year":"2018","journal-title":"J Back Musculoskelet Rehabil"},{"key":"B34","doi-asserted-by":"publisher","first-page":"R39","DOI":"10.1186\/ar2645","article-title":"Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis","volume":"11","author":"Chen","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","article-title":"ACR\/EULAR 2010 rheumatoid arthritis classification criteria","volume":"51","author":"Kay","year":"2012","journal-title":"Rheumatol Oxf Engl"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1128\/IAI.68.7.3965-3970.2000","article-title":"Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model","volume":"68","author":"Wang","year":"2000","journal-title":"Infect Immun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00011-008-8100-z","article-title":"Helicobacter pylori induces the release of alpha-defensin by human granulocytes","volume":"58","author":"Kocsis","year":"2009","journal-title":"Inflamm Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/j.1365-2567.2008.02997.x","article-title":"High \u03b1-defensin levels in patients with systemic lupus erythematosus","volume":"127","author":"Sthoeger","year":"2009","journal-title":"Immunology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1471-4906(03)00062-0","article-title":"Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules","volume":"24","author":"Roth","year":"2003","journal-title":"Trends Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/ard.2006.064741","article-title":"Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis","volume":"66","author":"Hammer","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2478\/jtim-2019-0026","article-title":"The role of calprotectin in rheumatoid arthritis","volume":"7","author":"Wang","year":"2019","journal-title":"J Transl Intern Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.matbio.2018.01.011","article-title":"TSG-6: a multifunctional protein with anti-inflammatory and tissue-protective properties","author":"Day","year":"2019","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1182\/blood-2010-12-327353","article-title":"Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2\/NF-\u03baB signaling in resident macrophages","volume":"118","author":"Choi","year":"2011","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/s41418-017-0006-2","article-title":"Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells","volume":"25","author":"Wang","year":"2018","journal-title":"Cell Death Differ"},{"key":"B45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.pharmthera.2016.07.015","article-title":"S100A8\/A9: from basic science to clinical application","volume":"167","author":"Pruenster","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41398-019-0378-9","article-title":"Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls","volume":"9","author":"Sellgren","year":"2019","journal-title":"Transl Psychiatry"},{"key":"B47","first-page":"309","article-title":"Neuropharmacology of quinolinic and kynurenic acids","volume":"45","author":"Stone","year":"1993","journal-title":"Pharmacol Rev"},{"key":"B48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5114\/ceji.2016.58815","article-title":"The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes - in vitro and ex vivo studies","volume":"41","author":"Ma\u0142aczewska","year":"2016","journal-title":"Cent Eur J Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jpba.2011.02.014","article-title":"Time-course of kynurenic acid concentration in mouse serum following the administration of a novel kynurenic acid analog","volume":"55","author":"Z\u00e1dori","year":"2011","journal-title":"J Pharm Biomed Anal"},{"key":"B50","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s00702-013-1146-2","article-title":"Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex","volume":"121","author":"Fejes-Szab\u00f3","year":"2014","journal-title":"J Neural Transm"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.3390\/molecules24193502","article-title":"Structural evaluation and electrophysiological effects of some kynurenic acid analogs","volume":"24","author":"Feh\u00e9r","year":"2019","journal-title":"Mol Basel Switz"},{"key":"B52","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fimmu.2020.0038","article-title":"IDO and kynurenine metabolites in peripheral and CNS disorders","volume":"11","author":"Huang","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T04:57:08Z","timestamp":1617944228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.632513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2021.632513"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.632513","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"article-number":"632513"}}